Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Receives CE Mark for Veristrat

Premium

Biodesix this week received an EU CE Mark for its Veristrat specimen collection and shipping kit, allowing the company to make Veristrat results available to physicians in the EU and other countries recognizing the CE Mark.

Veristrat is a blood-based proteomic diagnostic that identifies non-small cell lung cancer patients likely to respond to chemotherapy or the EGFR inhibitor Tarceva (erlotinib). Biodesix launched sales of the test in the US out of its CLIA lab in 2009 and has since performed more than 5,000 tests.

“Making VeriStrat results available to physicians for patients in the European Union has been an important goal for Biodesix,” Biodesix CEO David Brunel said in a statement. "With the CE Mark for the specimen collection and shipping kit, more physicians can incorporate this valuable new component into the set of tools they need to guide therapy."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.